Recent advances in antiretroviral drugs

RK Ghosh, SM Ghosh, S Chawla - Expert opinion on …, 2011 - Taylor & Francis
Importance of the field: Acquired immunodeficiency syndrome (AIDS) is one of the leading
causes of death worldwide. Although the combination therapies of highly active antiretroviral …

COVID-19: therapeutic approaches description and discussion

GG Trindade, SMC Caxito, AREO Xavier… - Anais da Academia …, 2020 - SciELO Brasil
Abstract: COVID-19 emerged in December 2019 in China, and since then, has disrupted
global public health and changed economic paradigms. In dealing with the new …

Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles

J Desai, H Thakkar - Journal of microencapsulation, 2016 - Taylor & Francis
The present investigation aimed to study the effect of particle size of solid lipid nanoparticles
(SLNs) on oral bioavailability of darunavir. High pressure homogenisation technique was …

Elucidating the interdependence of drug resistance from combinations of mutations

DA Ragland, TW Whitfield, SK Lee… - Journal of chemical …, 2017 - ACS Publications
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag
and Gag-Pro-Pol polyproteins in the viral genome. Under the selective pressure of protease …

The higher barrier of darunavir and tipranavir resistance for HIV-1 protease

Y Wang, Z Liu, JS Brunzelle, IA Kovari… - Biochemical and …, 2011 - Elsevier
Darunavir and tipranavir are two inhibitors that are active against multi-drug resistant (MDR)
HIV-1 protease variants. In this study, the invitro inhibitory efficacy was tested against a MDR …

Steady‐state pharmacokinetic interactions of darunavir/ritonavir with lipid‐lowering agent rosuvastatin

D Samineni, PB Desai, L Sallans… - The Journal of …, 2012 - Wiley Online Library
HIV‐1 protease inhibitors often cause dyslipidemia, necessitating the use of lipid‐lowering
agents such as rosuvastatin. However, when given concomitantly, these therapeutic agents …

Identifi cation of protease exosite-interacting peptides that enhance substrate cleavage kinetics

AM Jabaiah, JA Getz, WA Witkowski, JA Hardy… - Biological …, 2012 - degruyter.com
Many peptidases are thought to require non-active site interaction surfaces, or exosites, to
recognize and cleave physiological substrates with high specifi city and catalytic effi ciency …

HIV-1 subtype diversity, phylogenetic analysis and study of drug resistance in strains circulating in the Ural Federal District

MV Piterskiy, AG Gusev, OA Khodakov… - Journal of …, 2022 - microbiol.crie.ru
Abstract Introduction. Ural Federal District (UFD) has been one of the most HIV-affected
areas in the Russian Federation during past 20 years. The total number of people living with …

[HTML][HTML] Разнообразие субтипов, филогенетический анализ и изучение лекарственной устойчивости штаммов ВИЧ-1, циркулирующих в Уральском …

МВ Питерский, АГ Гусев, ОА Ходаков… - Журнал …, 2022 - cyberleninka.ru
Введение. Уральский федеральный округ (УФО) является одной из наиболее
эпидемически неблагополучных территорий в Российской Федерации по ВИЧ …

[PDF][PDF] A novel RP-HPLC method for the quantification of tipranavir in formulations

PVV Satyanarayana, AS Madhavi - IJAPBC, 2012 - ijapbc.com
ABSTRACT A simple, precise and accurate RP-HPLC method was developed and validated
for rapid assay of Tipranavir in tablet dosage form. Isocratic elution at a flow rate of 1ml/min …